Usana Health Sciences

Genaissance Pharmaceuticals Analyzed Samples for United States Department of Agriculture in Mad Cow Disease Investigation - Opportunity for Entry into Animal DNA Testing Market - NEW HAVEN, Conn., Jan 09, 2004 /PRNewswire-FirstCall via Comtex/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC) announced today that it had completed an analysis of DNA samples for the United States Department of Agriculture (USDA) as part of the USDA's effort to trace the origin of the animal infected with bovine spongiform encephalopathy or Mad Cow disease. "We were honored that the USDA asked us to analyze these very important samples," said Gerald F. Vovis, Ph.D., Executive Vice President and Chief Technology Officer of Genaissance Pharmaceuticals. "We had our personnel standing by to receive the samples when they arrived by courier and then worked around the clock to ensure that the results were available as rapidly as possible." "We see the use of DNA testing for animal identity and traceability as a new market opportunity for us and another step in the execution of our strategy to build a profitable base services business while developing proprietary products based on our HAP(TM) Technology," Dr. Vovis continued. "We believe that we have the experience to be a major player in this arena because we have an accredited genotyping laboratory that has a high-throughput process for analyzing DNA, including a proprietary laboratory information management system, the necessary robotics and microarray instrumentation. During the past year, we used this platform to generate over 8,000,000 DNA analysis results for our customers." Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of a new generation of DNA-based diagnostic and therapeutic products. Genaissance markets its technology, clinical development skills and pharmacogenomic services to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with major pharmaceutical, diagnostic and biotechnology companies. Genaissance is headquartered in Science Park in New Haven, Connecticut. Visit the company's website at www.genaissance.com. This press release contains forward-looking statements, including statements about the expected growth and development of Genaissance's business and market opportunities, the ability of Genaissance to apply its technologies to the development, marketing and prescribing of drugs and to detect associations between clinical outcomes and genetic variation. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to in such statements, including, but not limited to, the extent to which genetic markers (haplotypes) are predictive of clinical outcomes and drug efficacy and safety, the attraction of new business and strategic partners, the adoption of our technologies by the pharmaceutical industry, the timing and success of clinical trials, competition from pharmaceutical, biotechnology and diagnostics companies, the strength of our intellectual property rights and those risks identified in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2003, and in other filings we make with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein represent the judgment of Genaissance as of the date of this release. Genaissance disclaims any obligation to update any forward-looking statement. SOURCE Genaissance Pharmaceuticals, Inc.

30 % auf 3,70.

Gruss E.

ste USNA ausgegraben. Ist glaub ich nur von uns zwei Hübschen durchgesprochen worden. Die "Mad Cows" waren ein Geschenk gratis für EDET. Auf baldige Zweiarmigkeit. ( ENCY fast durch die 10, alter Freak ) Gruss E.